Accepted for/Published in: JMIR Formative Research
Date Submitted: Apr 4, 2025
Open Peer Review Period: Apr 16, 2025 - Jun 11, 2025
Date Accepted: Jan 12, 2026
(closed for review but you can still tweet)
Smart technology-assisted patient-centered management in venous thromboembolism: a pilot study on anticoagulation adherence
ABSTRACT
Background:
Mobile health (mHealth) technologies show promise in addressing suboptimal anticoagulation adherence among venous thromboembolism (VTE) patients
Objective:
To evaluate the impact of a mobile VTE application (mVTEA) on thromboprophylaxis adherence in VTE or moderate-to-high-risk patients.
Methods:
This single-center pilot study enrolled 88 patients at the Chinese PLA General Hospital (August–December 2023). Participants used mVTEA for automated medication reminders and self-management. Adherence was assessed using the Morisky Medication Adherence Scale-8 (MMAS-8) and Beliefs about Medicines Questionnaire-Specific (BMQ-Specific). Real-time adherence data were analyzed at 1 month (Trial registration: ChiCTR2200063206).
Results:
Among 45 completers (age 60.8±15.2 years; 35.6% female), baseline adherence was suboptimal (good: 28.9%; moderate/poor: 71.1%). Primary non-adherence drivers included forgetfulness (Q2: 0.69±0.47) and premature discontinuation (Q6: 0.78±0.42). BMQ-Specific revealed higher necessity than concern scores (17.58±3.12 vs. 14.58±3.34, p<0.001). At 1-month follow-up, 100% achieved perfect adherence, with 80% completing mVTEA check-ins. Patients utilizing check-in features demonstrated superior necessity-concern differentials (NCD>0: 80.6% vs. 0%, p<0.001). No adverse events occurred.
Conclusions:
mVTEA significantly improved short-term anticoagulation adherence through behavioral nudges and real-time monitoring. Individualized patient education may further optimize outcomes. Clinical Trial: ChiCTR2200063206
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.